AI-Based Virtual Screening of NLRP3 Inflammasome-Targeting Drug Candidates for Alzheimer’s Disease and Evaluation of Blood–Brain Barrier Permeability
Main Article Content
Keywords
NLRP3 inflammasome, Alzheimer’s disease, artificial intelligence, blood-brain barrier, machine learning
Abstract
Alzheimer’s disease (AD) is the leading cause of dementia in the elderly. Traditional drugs targeting Aβ and Tau proteins face development bottlenecks. In recent years, studies have shown that NLRP3 inflammasome-mediated neuroinflammation in the brain is a key mechanism in the pathogenesis of AD. However, the number of existing NLRP3-specific inhibitors is limited, and they generally suffer from insufficient blood-brain barrier (BBB) penetration. This study aims to combine artificial intelligence (AI) and machine learning technologies to construct a multi-task screening model that can simultaneously predict the inhibitory activity of small molecule NLRP3 and its ability to penetrate the blood-brain barrier, providing an efficient and low-cost computational screening technology solution for the development of novel anti-inflammatory drugs for Alzheimer's disease. It uses AlphaFold to obtain target protein structures and combines them with the ZINC20/PubChem chemical database to construct a compound dataset. Using Python as the core tool, a random forest multi-task machine learning model was built using the Google Colab cloud platform. Physicochemical parameters such as molecular weight, lipid solubility (LogP), and polar surface area (TPSA) were selected as input features for the model. The drug’s NLRP3 activity and BBB penetration were used as the core prediction labels for model training and cross-validation. The model demonstrated high predictive performance in 5-fold cross-validation, with an average accuracy of 68.89% for predicting NLRP3 activity and an average accuracy of 97.78% for predicting blood-brain barrier penetration. Feature importance analysis confirmed that LogP and TPSA are the most critical physicochemical features that determine whether candidate molecules can penetrate the blood-brain barrier. Several candidate small molecules with both NLRP3 inhibition potential and BBB penetration were screened from a large-scale candidate molecule library. This study successfully constructed a low-cost, easy-to-implement AI-assisted drug screening system for neurological diseases, which can provide data support for the development of lead compounds for novel anti-inflammatory targeted drugs for Alzheimer's disease.
References
- [1]Guerreiro, R., Wojtas, A., Bras, J., et al. (2013). TREM2 variants in Alzheimer’s disease. New England Journal of Medicine, 368(2), 117–127.
- [2]McGroarty, J., Salinas, S., Evans, H., et al. (2025). Inflammasome-mediated neuroinflammation: A key driver in Alzheimer’s disease pathogenesis. Biomolecules, 15(5).
- [3]Ayyubova, G., & Madhu, L. N. (2025). Microglial NLRP3 inflammasomes in Alzheimer’s disease pathogenesis: From interaction with autophagy/mitophagy to therapeutics. Molecular Neurobiology, 62(6), 7124–7143.
- [4]Vamathevan, J., Clark, D., Czodrowski, P., et al. (2019). Applications of machine learning in drug discovery and development. Nature Reviews Drug Discovery, 18(6), 463–477.
- [5]Alshehri, Z. S. (2025). Integrating artificial intelligence with small molecule therapeutics and precision medicine for neurochemical understanding of Alzheimer’s diseases. Neuroscience, 586, 44–57.
- [6]Heneka, M. T., Kummer, M. P., Stutz, A., et al. (2012). NLRP3 is activated in Alzheimer’s disease and contributes to pathology in APP/PS1 mice. Nature, 493(7434), 674–678.
- [7]Ising, C., Venegas, C., Zhang, S., et al. (2019). NLRP3 inflammasome activation drives tau pathology. Nature, 575(7784), 669–673.
- [8]Li, Z., & Gong, C. (2025). NLRP3 inflammasome in Alzheimer’s disease: Molecular mechanisms and emerging therapies. Frontiers in Immunology, 16, 1583886.
- [9]Chen, Y., Kou, Y., Ni, Y., et al. (2025). Microglia efferocytosis: An emerging mechanism for the resolution of neuroinflammation in Alzheimer’s disease. Journal of Neuroinflammation, 22, 96.
- [10]Zheng, Q., & Wang, X. (2025). Alzheimer’s disease: Insights into pathology, molecular mechanisms, and therapy. Protein & Cell, 16, 83–120.
- [11]Moradi, F., & Mokhtari, T. (2025). Role of NLRP3 inflammasome in chronic pain and Alzheimer’s disease—A review. Journal of Biochemical and Molecular Toxicology, 39(2), e70071.
- [12]Alkhalifa, A. E., Al-Ghraiybah, N. F., Odum, J., et al. (2023). Blood-brain barrier breakdown in Alzheimer’s disease: Mechanisms and targeted strategies. International Journal of Molecular Sciences.
- [13]Sweeney, M. D., Zhao, Z., Montagne, A., et al. (2019). Blood-brain barrier: From physiology to disease and back. Physiological Reviews, 99(1), 21–78.
- [14]Montagne, A., Nation, D. A., Sagare, A. P., et al. (2020). APOE4 leads to blood–brain barrier dysfunction predicting cognitive decline. Nature, 581(7806), 71–76.
- [15]Ding, Y. N., Li, M. Q., Ding, P. T., et al. (2026). Complement C1q-targeted microglial membrane camouflaged nanolipid carriers for synaptic protection in Alzheimer’s disease: A bioinspired alectinib delivery strategy. Nano Letters, 26(4), 1181–1191.
- [16]Liu, G., & Sun, Y. (2025). Harnessing nanoparticles for Alzheimer’s disease: Innovations in drug delivery and pathology-specific treatments. Journal of Alzheimer’s Disease, 107(4), 1374–1399.
- [17]Dong, N., Ali-Khiavi, P., Ghavamikia, N., et al. (2025). Nanomedicine in the treatment of Alzheimer’s disease: Bypassing the blood-brain barrier with cutting-edge nanotechnology. Neurological Sciences, 46(4), 1489–1507.
- [18]Xiao, B., Chen, Y. Q., & Wang, S. (2026). Integrative multi-omics and machine learning analysis identifies therapeutic targets and drug repurposing candidates for Alzheimer’s disease. Biomedicines, 14(5).
- [19]Rodriguez, S., Hug, C., Todorov, P., et al. (2021). Machine learning identifies candidates for drug repurposing in Alzheimer’s disease. Nature Communications, 12(1).
- [20]Zhang, X. W., Zhu, X. X., Tang, D. S., et al. (2023). Targeting autophagy in Alzheimer’s disease: Animal models and mechanisms. Zoological Research, 44(6), 1132–1145.
- [21]Kumar, B. S., Dinesh, B. G. H., Ganjipete, S., et al. (2025). Machine learning guided virtual screening of FDA approved drugs targeting GSK-3β in Alzheimer’s disease. Scientific Reports, 15(1), 45762.
- [22]Lyu, J., Irwin, J. J., & Shoichet, B. K. (2023). Modeling the expansion of virtual screening libraries. Nature Chemical Biology, 19(6), 712–718.
- [23]Liu, F., Mailhot, O., Glenn, I. S., et al. (2024). The impact of library size and scale of testing on virtual screening. bioRxiv.
- [24]Schneider, G. (2010). Virtual screening: An endless staircase? Nature Reviews Drug Discovery, 9(4), 273–276.
- [25]Fang, E. F., Hou, Y., Palikaras, K., et al. (2019). Mitophagy inhibits amyloid-β and tau pathology and reverses cognitive deficits in models of Alzheimer’s disease. Nature Neuroscience, 22(3), 401–412.
Article Sidebar
This work is licensed under a Creative Commons Attribution 4.0 International License.